Navigation Links
Small-Cell Lung Cancer Drug Market Will More Than Double to Over $684 Million in 2017
Date:4/8/2009

Although Market Growth Will be Robust, Drug Development Has Been Disappointing in Recent Years, According to a New Report from Decision Resources

WALTHAM, Mass., April 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the small-cell lung cancer drug market will more than double from just under $250 million in 2007 to more than $684 million in 2017, owing to the launches of Genentech/Roche/Chugai's Avastin and Celgene's amrubicin (currently marketed in Japan as Calsed by Nippon Kayaku) to treat the indication.

The new Pharmacor report entitled Small-Cell Lung Cancer finds that the launches, beginning in 2012, of Avastin as a first-line add-on to standard chemotherapy and amrubicin as a second-line therapy will drive robust 22 percent annual growth from 2012 to 2017 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although market growth will be robust from 2012 to 2017, drug development in recent years in small-cell lung cancer has, overall, been very disappointing. Recent clinical trials have largely eliminated Pfizer's Camptosar/Campto (Daiichi Sankyo's Topotecin), Eli Lilly's Alimta, and GlaxoSmithKline/Nippon Kayaku's Hycamtin from potential first-line status in the indication. Furthermore, despite the impressive sales that Avastin and amrubicin will add to the market, these therapies will have only niche roles in small-cell lung cancer treatment.

"Avastin and amrubicin will each garner only a limited share of the total small-cell lung cancer patient population," said Decision Resources Analyst Janie Mackay, Ph.D. "However, their high price points in an increasingly generic market, mean that those patient shares will translate into substantial market shares."

Despite the disappointing drug development environment, the recent designation
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 2014 Recently, Skmen.com, an outstanding company in ... bohemian dresses . In addition to this, the company ... Now, all of them are available at low rates, up ... product design and quality. Its beautiful bohemian outfits are available ... many others. Owing to its top quality clothes, reasonable prices ...
(Date:8/19/2014)... 19, 2014 Kars4Kids , a ... announced today its partnership with New York State Senator ... in the Bronx. The giveaway will take place in ... Crotona Park on August 22. , “With a ... believe properly preparing children for school with the necessary ...
(Date:8/19/2014)... has recently compared many popular hosting suppliers and announced ... recommended companies for webmasters who want to buy high ... an affordable price. , Both GoDaddy and iPage ... the lowest upfront costs (including some Joomla hosting products ... of options. , GoDaddy is a famous supplier ...
(Date:8/19/2014)... 19, 2014 Grande Naturals, LLC ... winner of the 2014 Independent Cosmetics Manufacturers & ... first place position in “Product Innovation; Product Color ... which also includes a lash enhancement serum, GrandeLINER™. ... lash-boosting technology. , This all-new eyeliner ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, ... be added to the list of possible harms related ... treat behavioral symptoms of dementia in older adults, a ... olanzapine (Zyprexa) are approved by the U.S. Food and ... serious mental disorders. They are also frequently used "off-label" ...
Breaking Medicine News(10 mins):Health News:2014 Bohemian Dresses Now for Sale at Skmen.com 2Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Top10BestSEOHosting.com: Cheap Joomla Hosting Reviews Unveiled 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3
... June 17 NeoMend, Inc. today announced,that its ... from the U.S. Food and Drug Administration,s (FDA) ... panel,s recommendation will be considered by the FDA ... (PMA) for ProGEL. The,panel,s recommendation for FDA approval ...
... BOSTON--Patients diagnosed with colon cancer who had abundant vitamin D ... follow-up period than those who were deficient in the vitamin, ... Institute. , The findings of the study -- the first ... patients -- merit further research, but it is too early ...
... Access to Personal ... Enrolls Nearly 1,000 Police Officers in MedeFile System During National ... ... Board: MDFI), a company specializing in,portable electronic medical records management solutions, today announced,that ...
... -- Research findings and innovative approaches offer the promise ... adults living with type 1 diabetes, according to researchers ... Forum in Washington D.C. , Type 1 diabetes is ... insulin-producing beta cells in the pancreas. It renders ...
... June 18 A CI head once noted that,"Competitive ... but the only,time you realize you need it is ... marketing space, most companies need competitive,intelligence to effectively deal ... insights are lacking that people begin to realize how,critical ...
... 18 Sunrise Senior Living,Inc. (NYSE: SRZ ), ... will present at the 2008 Jefferies 2nd Annual,Healthcare Conference ... 1:30 p.m.,Eastern Time. Sunrise will Web cast the presentation ... http://www.sunriseseniorliving.com ). A replay of the Web cast will ...
Cached Medicine News:Health News:NeoMend Receives FDA Panel's Recommendation for Approval of ProGEL(TM) Surgical Sealant 2Health News:Study links vitamin D to colon cancer survival 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 2Health News:MedeFile International Teams with Newark Fraternal Order of Police 3Health News:MedeFile International Teams with Newark Fraternal Order of Police 4Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 2Health News:Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum 3Health News:Build and Maintain an Effective Competitive Intelligence Group 2
(Date:8/19/2014)... Aug. 19, 2014 Minimally Invasive Devices Inc. ... device company, announced today that Mitsubishi Corporation has formally ... visualization system in Japan . MID ... Japan in the second half ... exclusive distributor for Karl Storz GMBH & Co. (endoscopic ...
(Date:8/19/2014)... , Aug. 19, 2014  Tokyo-based Atonarp ... A funding round led by Walden Riverwood Ventures ... the development of Atonarp,s Smart Spectrometer technology platform, ... The company has targeted the oil & gas ... "We are excited to partner with Atonarp ...
(Date:8/19/2014)...  Boehringer Ingelheim today announced that the U.S. ... the New Drug Application (NDA) for the fixed-dose ... the Respimat ® inhaler for the proposed ... obstruction in patients with chronic obstructive pulmonary disease ... olodaterol FDC will not be indicated to treat ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8
... Based on decades of experience, the SSD-1000 ... ultrasound system. It uses our advanced technologies ... experience. Using the same technology as our ... imaging capabilities in a compact and mobile ...
... Using pulsed radiofrequncy current, ... system quickly heats and ablates ... it in minimal time., RF ... in open surgery, percutaneously, or ...
... a biologically based adhesive supplied as ... consisting of a liquid substrate and ... internal bleeding. When combined ... to a prepared wound and tenaciously ...
... (Human) achieves a secure clot, targeted to ... for hemostasis is needed, when control of ... ligature, and cautery, is ineffective or impractical., ... formulation of human Biologically Active Component (BAC) ...
Medicine Products: